Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929847 | 0.87 | HAO1 (0.50) | LMNAHAO1HTTKMT2AHPGD | |
| SCHEMBL3121665 | 0.85 | GRM5 (0.50) | LMNAHAO1TSHRMAP3K14 | |
| SCHEMBL1637026 | 0.84 | L3MBTL1 (0.52) | LMNAHAO1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL8615592 | 0.84 | ACACB (0.57) | ACACBLMNAALDH1A1HTTMEN1 | |
| SCHEMBL3942298 | 0.83 | LMNA (0.47) | LMNAHAO1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL11443850 | 0.82 | HAO1 (0.46) | LMNAHAO1L3MBTL1HTTTSHR | |
| SCHEMBL10411220 | 0.80 | ACACB (0.51) | ACACBLMNAALDH1A1HTTMEN1 | |
| SCHEMBL845317 | 0.80 | GRM5 (0.52) | L3MBTL1ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL1637191 | 0.79 | ABCC9 (0.44) | LMNAHAO1L3MBTL1ALDH1A1HTT | |
| SCHEMBL12724811 | 0.79 | ACACB (0.50) | ACACBLMNAHAO1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042506-B1 | SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX | UBE INDUSTRIES (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-7932398-B2 | Substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex | UBE INDUSTRIES, LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932398-B2 | Substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex | UBE INDUSTRIES, LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090234130-A1 | SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX | UBE INDUSTRIES, LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090234130-A1 | SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX | UBE INDUSTRIES, LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2042506-A1 | SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX | Ube Industries, Ltd. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234130-A1 | SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX | CCRL2, CCNL2, ATXN2L | ACACB 1251/4885LMNA 2002/4885HAO1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.